The rise of GLP‑1 weight‑loss drugs is creating both challenges and opportunities for red meat consumption, new analysis from the Agriculture and Horticulture Development Board (AHDB) has shown.
GLP‑1 (glucagon-like peptide) medications, originally developed to treat type-2 diabetes and obesity, work by suppressing appetite, slowing digestion and altering taste perception.
As a result, users typically eat less food overall, favour smaller portions and increasingly prioritise nutrient‑dense, protein‑rich foods.
According to AHDB, this shift has “important implications for red meat”.
It said: “While overall food intake among GLP‑1 users is reduced, emerging evidence suggests protein remains a dietary priority.”
According to February 2026 data from a YouGov/AHDB tracker, of those people who are taking GLP-1, 85% report eating less food overall, while 43% report eating more protein-dense foods such as meat and fish.
Vanessa Adamson, retail and consumer insight manager at AHDB, said: “GLP‑1 drugs are driving a clear shift towards ‘less but better’ eating.
“Although consumers may be buying smaller quantities, protein remains central to their diets, and research suggests many are willing to spend more on high‑quality meat when they do purchase it.”
For red meat, this presents an opportunity to focus on lean, nutrient‑dense cuts and premium products, such as steaks and pork tenderloins, that align with the health priorities of GLP‑1 users, particularly protein for satiety and muscle maintenance.”
Consumer demand
According to AHDB, evidence from international research supports this trend.
It said: “A large US food demand study found that while GLP‑1 users reduced overall food consumption, they showed a higher willingness to pay for high‑quality meat and seafood, suggesting a potential shift towards premiumisation rather than complete avoidance.
“At the same time, GLP‑1 users report cutting back most sharply on ultra‑processed, calorie‑dense foods and takeaways.”
AHDB added that this “may pose a challenge for processed meat products and some out‑of‑home channels but reinforces growing consumer interest in more natural, minimally processed protein sources”.
“Retailers are already starting to respond, with the launch of smaller‑portion, nutrient‑dense meal options designed to meet the needs of consumers with reduced appetites,” AHDB said.
It noted that similar approaches could support red meat consumption by offering “convenience, clear protein credentials and appropriate portion sizes”.
Adamson added: “Red meat is well placed to remain part of a balanced diet for GLP‑1 users, particularly where messaging focuses on lean cuts, quality and nutritional value.
“The key will be meeting changing consumer needs with the right products, portions and communication.”
Dairy
Earlier this year, AHDB said that the dairy industry is “well-positioned to respond” to the rise of GLP-1, particularly “by leaning into its protein-rich whey products”.
“However, an effort needs to be made to highlight the nutritional value of dairy, and raw ingredients alone might not be enough,” AHDB said.
“Providing nutritionally complete, convenient, pre-packed dairy options with attention to portion sizes will be key to winning these consumers.”